Related Experiment Video
Updated: May 15, 2026
Combination of High Ligation and Intraoperative Embolization Using Polidocanol for Treatment of Varicoceles
Published on: December 22, 2023
Technical and Clinical Outcomes of Embolization of Hypervascular Renal Tumors Using Tantalum-Loaded Obsidio
Sandra Gad1,2, Michael Mohnasky3, Zachary Schrank3
1Division of Vascular & Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Drive Chapel Hill, North Carolina, NC 27514, USA.
Purpose:
To evaluate the efficacy and safety of renal artery embolization (RAE) in hypervascular renal tumors using Tantalum-Loaded Obsidio™ Conformable Embolic (Ta-OCE).
Methods:
A single-center institutional review board (IRB) approved retrospective analysis of consecutive patients with benign and malignant hypervascular renal tumors treated with Ta-OCE between May 2023 and June 2024 was performed. Specific clinical data on tumor size reduction, renal function preservation, bleeding, and complications were collected. Follow-up imaging was conducted using MRI or CT scans. Adverse events were evaluated according to the Common Toxicity Criteria for Adverse Events (v.5). Student's t-test was used to compare continuous variables.
Results:
Overall, N = 10 patients (mean age 64.1 + 14.9 (SD) years, 46% female) were included; 5 patients with renal cell carcinoma (RCC) and 5 patients with angiomyolipoma (AML). Technical success was achieved in all 10 patients. There was a significant reduction in tumor diameter of 1.03 cm following embolization (p = 0.0009). There was no significant change in renal function post-RAE at 1 month, GFR pre-(72.8 ± 23.5 mL/min/1.73 m2, GFR post 63 ± 24.7 mL/min/1.73 m2, with a mean change in GFR (%) of - 13.5 ± 11.2%. (p = 0.116). Additionally, no significant bleeding requiring further intervention was experienced. One patient experienced a Grade 1 adverse effect due to an underlying heart condition.
Conclusion:
Embolization of hypervascular renal tumors with Ta-OCE appears to be safe and effective. Prospective, ideally multicenter studies are needed to further clarify the ideal scenarios for the use of Ta-OCE in hypervascular renal tumors.
